Clinical best response to MEL200 or MEL100
| Response . | MEL200 (N = 149), no. of patients (%) . | MEL100 (N = 149), no. of patients (%) . | P* . |
|---|---|---|---|
| Complete, very good partial, or partial response | 117 (78.5) | 107 (71.8) | .23 |
| Complete response | 22 (14.8) | 12 (8.1) | .07 |
| Very good partial response | 33 (22.1) | 20 (13.4) | |
| Partial response | 62 (41.6) | 75 (50.3) | |
| Stable disease | 27 (18.1) | 34 (22.8) | .31 |
| Progressive disease | 1 (0.7) | 5 (3.4) | .10 |
| Not available | 4 (2.7) | 3 (2.0) | .7 |
| Response . | MEL200 (N = 149), no. of patients (%) . | MEL100 (N = 149), no. of patients (%) . | P* . |
|---|---|---|---|
| Complete, very good partial, or partial response | 117 (78.5) | 107 (71.8) | .23 |
| Complete response | 22 (14.8) | 12 (8.1) | .07 |
| Very good partial response | 33 (22.1) | 20 (13.4) | |
| Partial response | 62 (41.6) | 75 (50.3) | |
| Stable disease | 27 (18.1) | 34 (22.8) | .31 |
| Progressive disease | 1 (0.7) | 5 (3.4) | .10 |
| Not available | 4 (2.7) | 3 (2.0) | .7 |
Seven patients were not evaluated because their follow-up was less than 1 month for lost to follow-up (6 patients) and withdrawal of consent (1 patient).
Proportions were compared with the use of the χ2 test or Fisher exact test.